GlaxoSmithKline plc (GSK.L)
| Previous close | 1,640.50 |
| Open | 1,638.50 |
| Bid | 1,636.00 x 0 |
| Ask | 1,636.50 x 0 |
| Day's range | 1,633.99 - 1,647.00 |
| 52-week range | 1,302.60 - 1,725.81 |
| Volume | |
| Avg. volume | 8,819,233 |
| Market cap | 66.848B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.63 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.64 (3.90%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Insider Monkey
20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
- Reuters
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
